Experimental Therapeutic Effects of Hybrid Liposomes on the Alzheimer's Disease in Vitro

Abstract

Accumulation of b amyloid (Ab) peptides to nerve cells should be associated with the onset of Alzheimer's disease (AD). We prepared hybrid liposomes (HL) composed of 90 mol％ phospholipids having various charged head groups (cationic L-a-dimyristoyltrimethyl ammonium propane (DMTAP), anionic L-a-dimyristoylphosphatidylserine (DMPS) or zwitterionic L-a-dimyristoylphosphatidylcholine (DMPC)) and 10 mol％ polyoxyethylene(23) dodecyl ether (C 12 (EO) 23 )), and investigated the inhibitory eŠects of HL on the accumulation of Ab 1 40 peptides into human neuroblastoma (SH-SY5Y) cells in vitro. It is noteworthy that remarkable inhibitory eŠects on the accumulation of Ab 1 40 peptides were observed for SH-SY5Y cells treated with anionic HL-DMPS, though the accumulation was not inhibited by cationic HL-DMTAP. On the other hand, the immediate fusion of HL-DMTAP into SH-SY5Y cells was conrmed using a confocal laser microscope. Interestingly, the speciˆc interactions between anionic HL-DMPS and Ab 1 40 peptides were observed using the thio‰avin T (ThT) assay. In addition, the cytotoxicity of Ab 1 42 peptides on the SH-SY5Y cells decreased after the treatment with HL-DMPS. These results suggest that anionic HL-DMPS could be used as a novel medicine for AD in the future.

Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease)

“…In the first study, they investigated the inhibitory effects of hybrid liposomes on the accumulation of amyloid beta 1-40 for SH-SY5Y cells. They prepared liposomes composed by phospholipids having various charged head groups (cationic L-alpha-dimyristoyltrimethyl ammonium propane (DMTAP), anionic L-alpha-dimyristoylphosphatidylserine (DMPS), or zwitterionic L-alpha-dimyristoylphosphatidylcholine (DMPC)) and polyoxyethylene(23) dodecyl ether (C(12)(EO)(23)), and found that the cytotoxicity of amyloid-beta (1-42) peptides on the SH-SY5Y cells decreased after the treatment with this formulation of liposomes [82]. In the other in vitro study, they applied unilamellar liposomes in HEK-APP cells, providing protection from oxidation and effective incorporation of omega-3 fatty acid docosahexaenoic acid (DHA) into cell membranes comparing with HEK293 control cells.…”

Global Initiative for Interdisciplinary Approach to Improve Innovative Clinical Research and Treatment Outcomes in Geriatrics: Biological Cell-Based Targeted Drug Delivery Systems for Geriatrics

“…If, during the last century researchers attempted to use cells as simple drug carriers or containers, as well as to improve encapsulation procedure for different drugs, then today DDS has developed more fascinating, complex, and interactive systems. [26][27][28][29][30][31][32][33][34][35][36] The main requirements for DDS include: (1) The drug should influence the pathological foci solely and must not have any side or toxic effects; (2) drug properties should remain intact on the way to the drug's destination, with mechanisms in place to control for over-dosage; and (3) there should be effective target reliability, which ensures that drugs reach their final settings. DDS can be conventional and can be target organ or tissue specific.…”